Group of affinity and photoreceptor proteins

By designing a specific affinity and photoreceptor protein combination and using red light for light-dependent control, the problem of difficulty in adding and precise manipulation of red light manipulation in the prior art is solved, and high efficiency for various proteins is achieved Light manipulation.

CN118974075APending Publication Date: 2024-11-15THE UNIV OF TOKYO +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029188.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-24
Filing Date
2023-03-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art has problems such as difficulty in adding cofactors, difficulty in precision manipulation and limited application scope when using red light for light manipulation, especially the poor light manipulation effect on various proteins.

Method used

A combination of affinite and photoreceptor protein was developed, and red light (600-750nm) was used for light-dependent control, and precise light manipulation of various proteins was achieved through specific amino acid sequence mutations and combination design.

Benefits of technology

It realizes precise and efficient light manipulation without using blue light but using two wavelengths of light at different lengths. It is suitable for various proteins and does not require cofactors, which improves the precision and efficiency of light manipulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005052442370000291
    Figure BDA0005052442370000291
  • Figure HDA0005052442380000011
    Figure HDA0005052442380000011
  • Figure HDA0005052442380000021
    Figure HDA0005052442380000021
Patent Text Reader

Abstract

The present invention provides a group of an affinity and a photoreceptor protein, in which the affinity and the photoreceptor protein form a complex in a light-dependent manner, and the wavelength of the light is 600-750 nm.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a combination of an affibody and a photoreceptor protein. In addition, the present invention relates to a transgenic technology using the combination of an affibody and a photoreceptor protein. Background Art

[0002] Molecular control approaches utilizing light activation of proteins have emerged, known as optogenetics. Light is more easily controlled in space and time than chemicals, and light-dependent protein-protein interaction systems utilizing light-sensitive proteins that form dimers in a light-dependent manner, photoreceptors, and their binding partners are known.

[0003] Patent Document 1 discloses, as a technique for photomanipulation using blue light, a group of proteins capable of controlling the formation and dissociation of dimers by irradiation with light, which is useful as a tool for optogenetics.

[0004] Non-patent documents 1 to 3 also report on techniques for manipulation using red light.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Japanese Patent Application Publication No. 2015-165776

[0008] Non-patent literature

[0009] Non-patent document 1: Nature Biotechnology, 2002, 20, 1041-1044

[0010] Non-patent document 2: Nature Methods, 2016, 13, 591-597

[0011] Non-patent literature 3: ACS Synth.Biol.2020,9,3322-3333 Summary of the invention

[0012] Problems to be solved by the invention

[0013] Although the technology of photomanipulation using red light is known, it is known that there are many problems such as the need to add cofactors, difficulty in manipulation using two different wavelengths of light, difficulty in precise manipulation, etc. In addition, there are also problems such as the inability to apply photomanipulation of various proteins.

[0014] The purpose of the present invention is to develop a photoswitch protein that uses two different wavelengths of light instead of blue light, and can precisely and efficiently photomanipulate the activities of various proteins.

[0015] Means for solving problems

[0016] The inventors of the present application have conducted intensive studies to solve the above-mentioned problems and, as a result, have found that a combination of an affibody and a photoreceptor protein can be photocontrolled by red light, thereby completing the present invention.

[0017] The present invention is as follows. [1]

[0019] A combination of an affibody and a photoreceptor protein, wherein

[0020] The affibody forms a complex with the photoreceptor protein in a light-dependent manner, and the wavelength of the light is 600 to 750 nm. [2]

[0022] The group as described in [1], wherein the affibody has an amino acid sequence of any one of the following (1) to (4):

[0023] (1) the amino acid sequence represented by SEQ ID NO: 1;

[0024] (2) an amino acid sequence represented by SEQ ID NO:1, wherein the amino acids corresponding to SEQ ID NO:1 are mutated at 1 to 5 positions among positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35;

[0025] (3) an amino acid sequence having 80% or more identity with the amino acid sequence of the amino acid sequence represented by SEQ ID NO:1 except for the amino acid sequences at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35;

[0026] (4) An amino acid sequence represented by SEQ ID NO: 1, wherein the corresponding amino acids in SEQ ID NO: 1 are mutated at 1 to 5 positions among positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35, and an amino acid sequence having 80% or more identity with the amino acid sequence of a portion other than positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35. [3]

[0028] The group as described in [1], wherein the Affibody has the following amino acid sequence (5) or (6):

[0029] (5) an amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid corresponding to SEQ ID NO: 1 is mutated at position 18 and / or position 24;

[0030] (6) An amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid corresponding to SEQ ID NO: 1 is mutated at position 18 and / or position 24, and the amino acid sequence has an identity of 80% or more with the amino acid sequence other than positions 18 and 24. [4]

[0032] The group as described in [1], wherein the Affibody has the following amino acid sequence (7) or (8):

[0033] (7) an amino acid sequence having an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M) at position 18 in the amino acid sequence represented by SEQ ID NO:1;

[0034] (8) An amino acid sequence represented by sequence number 1, which has an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M) at position 18, and has an amino acid sequence with a homology of more than 80% with the amino acid sequence of the portion other than position 18. [5]

[0036] The group as described in [1], wherein the affinity body has the following amino acid sequence (9):

[0037] (9) An amino acid sequence represented by SEQ ID NO: 1, wherein at position 18, there is an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M), and 1 to 5 amino acids are missing from the N-terminus or C-terminus of SEQ ID NO: 1. [6]

[0039] The set according to any one of [1] to [5], wherein the photoreceptor protein is DrBphP. [7]

[0041] The group according to any one of [1] to [6], wherein the photoreceptor protein has:

[0042] (1) the amino acid sequence represented by SEQ ID NO: 2; or

[0043] (2) An amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 2. [8]

[0045] The set according to any one of [1] to [7], wherein the domain associated with gene transcription activity is bound to one of the affibody and the photoreceptor protein, and the nucleic acid recognition domain is bound to the other of the affibody and the photoreceptor protein. [9]

[0047] The group according to any one of [1] to [8], wherein one of the fragments of the protein having a predetermined action cleaved into two fragments binds to the affinity body,

[0048] The protein with the required function is split into two pieces, and the other piece binds to the light receptor protein.

[0049] Effects of the Invention

[0050] The present invention can provide a photoswitch protein that uses two different wavelengths of light instead of blue light, and can precisely and efficiently perform photomanipulation of the activities of various proteins. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] [ Figure 1 ] Figure 1 MagRed is explained. MagRed refers to a combination of a photoreceptor protein such as DrBphP and an affinity body. In the figure, an example of using DrBphP as a photoreceptor protein is explained. In addition, in the figure, the affinity body is recorded as a Pfr specific bidding partner. (a) A schematic diagram of DrBphP and an affinity body that is specific to its photo-state (Pfr) morphology is shown. (b) A diagram showing residues that may be randomized in the crystal structure of the affinity body (PDB: 2M5A) depicted in ball-filling mode. (c) A schematic diagram of a gene expression system based on the tetR-tetO system using DrBphP and an affinity body that is specific to its photo-state (Pfr) morphology is shown. When irradiated with 660nm light, the Affibody connected to VP16 and the nuclear localization sequence (NLS) binds to tetR-DrBphP bound to the tetO sequence, activating the transcription of the reporter gene (fluc: firefly luciferase) (Pmin: minimal cytomegalovirus promoter). (d) shows the alignment of the amino acid sequences of the Affibody (Aff6) and its mutants (Aff6_V18F and Aff6_V18FΔN) obtained by screening on the N-terminal side. It should be noted that Aff6, Aff6_V18F and Aff6_V18FΔN show partial sequences of the amino acid sequences of the Affibody (SEQ ID NOs. 63 to 65). (e) shows the results of comparing the bioluminescence intensity of HeLa cells introduced with a bioluminescence reporter plasmid using a combination of a transcription activator (Aff6-VP16-NLS) into which the affimer (Aff6) and its mutants (Aff6_V18F and Aff6_V18FΔN) obtained by screening were introduced and the full-length form of DrBphP (FL).

[0052] [ Figure 2 ] Figure 2 The results of evaluating the binding and dissociation of MagRed by a split luciferase assay are shown. (a) A schematic diagram of the split luciferase assay. When irradiated with 660nm light, the two fragments (fluc-N398 and fluc-C394) of the split luciferase fused to MagRed (DrBphP and Aff6_V18FΔN) bind to each other, and the bioluminescent signal increases. When irradiated with 800nm ​​light, the two fragments of the split luciferase fused to MagRed dissociate and the bioluminescent signal decreases. (b) A schematic diagram of the domain structure of the fusion protein used in the split luciferase assay. (c) Repeated 660nm (10W / m 2 ) for 1 minute and 800nm ​​(50W / m 2 (d) shows the time course of changes in bioluminescence of the split-luciferase fused to MagRed and the bioluminescence of the full-length luciferase (fluc) when irradiated with 660 nm light for 5 minutes. The bioluminescence signal was normalized to the minimum intensity in each sample. (e) shows the time course of changes in bioluminescence of the split-luciferase fused to MagRed and the full-length luciferase (fluc) when irradiated with 660 nm light (10 W / m 2 ) Time curve of bioluminescence from split luciferase within 30 minutes after PCR. The bioluminescent signal was normalized to the minimum intensity in each sample.

[0053] [ Figure 3 ] Figure 3The results of comparing MagRed and RpBphP1-PpsR2 / QPAS1 in a photomanipulation system (CPTS) for gene expression using CRISPR-Cas9 are shown. (a) A schematic diagram of Red-CPTS into which MagRed has been introduced is shown. dCas9 binds to the guide RNA (sgRNA) into which the MS2-RNA aptamer has been introduced and thereby binds to genomic DNA. The proteins (DrBphP and Aff6_V18FΔN) that constitute MagRed are fused to the transcriptional activation domain (p65-HSF1) and the MS2 protein. When irradiated with 660nm light, p65-HSF1 is recruited to the target locus by the activity of MagRed, thereby activating the transcription of the target gene. (b, c, d) The comprehensive structure of the CPTS obtained by fusing BphP or its binding partner to either the N-terminus or the C-terminus of the transcriptional activation domain (p65-HSF1) and the MS2 protein is shown. The combinations of MS2 protein and transcriptional activation domain (p65-HSF1) tested are shown in (b). For all combinations tested, the average value of the ratio of light state response to dark state response is shown in (c) with an actual data scale, and the average value is made into a heat map in log2 scale and shown in (d). These ratios of light state response to dark state response are calculated based on the bioluminescence intensity of HEK293T cells introduced with CPTS and bioluminescent reporter plasmids. (e, f) The experimental conditions are the same as (c) and (d). For the control using the C20A mutant or C20S mutant of RpBphP1, in (e), a high luminescence intensity equivalent to that of the wild type (WT) of RpBphP1 is shown under red light conditions, but in (f), the luminescence completely disappears.

[0054] [ Figure 4 ] Figure 4 The results of photomanipulation of gene expression in mammalian cells using CPTS (Red-CPTS) with MagRed introduced are shown. (a) The results of photomanipulation of gene expression using Red-CPTS using MagRed and CRISPR-Cas9 are shown. Different designs of Red-CPTS were prepared and evaluated using the bioluminescence intensity of HEK 293T cells as an indicator. The designs of each composition (#1 and #3) are shown in Figure 3. It is shown that by connecting two or more Aff6_V18FΔN constituting MagRed in a series, the gene expression activity of Red-CPTS can be greatly enhanced. The column on the right represents the response when irradiated with red light, and the column on the left represents the response in the dark. The ratio (numerical value) of the response when irradiated with red light to the response in the dark is shown in the upper part of the figure. (b) Shows the results of using a mixture of guide RNAs (gRNAs) targeting endogenous genes ASCL1, HBG1, IL1R2, and MYOD1 in HEK 293T cells, and simultaneously activating the genes with red light.

[0055] [Figure 5] Figure 5 shows a red light-driven DNA recombination system using MagRed. (a) A schematic diagram of RedPA-Cre is shown. When irradiated with 660nm light, the activity of MagRed causes the two fragments of the Cre recombinase split body (split Cre) to combine and activate, and a recombination reaction of the DNA sandwiched by two loxP sequences occurs. (b) Four structures involving the fusion of the Cre recombinase split body (split Cre) with BphP and its binding partner are shown. The ratio of their light state response to dark state response is calculated based on the bioluminescence intensity of HEK 293T cells into which plasmids of RedPA-Cre and bioluminescent reporter genes designed respectively are introduced. (c, d) For all combinations tested, the average value of the ratio of light state response to dark state response is plotted in (c) using the actual data scale, and the average value is shown in (d) as a heat map using the log2 scale. The ratio of their light state response to dark state response was calculated based on the bioluminescence intensity of HEK293T cells into which the four designed RedPA-Cre and bioluminescent reporter plasmids were introduced. (e) The experimental results of the fluorescent reporter system (mCherry, detected using the RFP channel of a fluorescent microscope) based on RedPA-Cre linked to a yellow fluorescent protein (Venus, detected using the GFP channel of a fluorescent microscope) are shown. The ratio of mCherry-positive cells among Venus-positive cells (mCh+ / GFP+) was estimated from more than 1,000 cells in three independent experiments. (f) Plasmids encoding RedPA-Cre and bioluminescent reporter plasmids that produce bioluminescence through DNA recombination reactions were introduced into the liver of mice by hydrodynamic tail vein injection (HTVinjection), and light was non-invasively irradiated with a red LED from outside the body. The results of comparing the bioluminescent images of mice raised in the dark and mice irradiated with red light are shown. For the expression of luciferase from the bioluminescent reporter plasmid, 200 μL of 100 mM D-luciferin was introduced into the peritoneal cavity of the mouse 25 hours after hydrodynamic tail vein injection, and bioluminescence was observed by imaging. (g) shows the results of comparing the bioluminescence intensity of mice raised in the dark and mice irradiated with red light. The horizontal lines and bars represent the mean ± sd bioluminescence intensity, and the points represent the bioluminescence intensity of each mouse.

[0056] [ Figure 6] shows the analysis results of 10 affimers obtained by ribosome display screening. The base sequences of the 10 affimers (Table 1) were respectively introduced into the upstream side of the base sequence of VP16-NLS to prepare constructs. These constructs were introduced into HeLa cells together with the constructs of tetR-DrBphP-PSM and SEAP reporter genes, and the 10 affimers were compared using bioluminescence intensity as an indicator. Zdk1 is an affimer that is unrelated to DrBphP-PSM (negative control). The analysis results are represented by the average of 3 data.

[0057] [ Figure 7 ] shows the comparison results when the amino acids of 12 of the 13 residues that may be randomized in Affi6 are replaced by alanine. The axis labels in the figure represent the amino acid residues substituted by alanine. The base sequence of Aff6 of the construct of Aff6-VP16-NLS was replaced with the base sequence of Aff6 substituted by alanine, and it was introduced into HeLa cells together with the construct of tetR-DrBphP and bioluminescent reporter gene, and the alanine substitution was compared with the bioluminescent intensity as an indicator. The results are represented by the mean ± standard deviation of 3 data. In addition, NS means P>0.05 (two-way ANOVA based on multiple comparisons).

[0058] [ Figure 8 ] shows the comparison results of the case where the 18th amino acid (valine, V) of Aff6 is introduced into a site-specific saturation mutation. The axis label in the figure represents the 18th amino acid (X) introduced into the Aff6_V18X mutant. The base sequence of Aff6 of the construct of Aff6-VP16-NLS was replaced with the base sequence of Aff6_V18X, and it was introduced into HeLa cells together with the construct of tetR-DrBphP and bioluminescent reporter gene, and the comparison of Aff6_V18X mutant was performed with bioluminescent intensity as an indicator. The results are represented by the mean ± standard deviation of 3 data. In addition, **** represents P < 0.0001 (two-way ANOVA based on multiple comparisons).

[0059] [ Fig. 9 ] Fig. 9 The activation of Red-CPTS in various cell lines is shown. The construct of Red-CPTS and bioluminescent reporter gene was introduced into HeLa cells (a) and Neuro 2a cells (b), and the activation of Red-CPTS was evaluated with bioluminescent intensity as an indicator. The ratio of the average bioluminescent intensity under the conditions of red light (right side of the bar graph) and darkness (left side of the bar graph) is expressed numerically. The results are expressed as the average of 3 data.

[0060] [ Fig.10 ] Fig.10The results of evaluating RedPA-Cre by a reporter gene assay are shown. (a) Schematic diagram of a reporter gene assay using RedPA-Cre. The expression of firefly luciferase (fluc) is in a state of being inhibited by a transcription stop signal (pA x3: polyadenylation transcriptional 'stop' signal tri-repeated sequence) located downstream of the CMV promoter (this reporter gene is called "Floxed-STOP fluc reporter gene"). When the two fragments of the split Cre recombinase (split Cre) are recombined by MagRed-induced Cre recombinase by irradiation with 660nm light, and the transcription stop signal sequence sandwiched by two loxP sites is deleted by a DNA recombination reaction using the activated Cre recombinase, the fluc reporter gene is expressed due to the activity of the promoter. (b) Schematic diagram of a reporter gene experiment based on RedPA-Cre linked to a yellow fluorescent protein (Venus) (here, a “Floxed-STOP mCherry reporter gene” was used in which the red fluorescent protein mCherry was expressed due to the activity of RedPA-Cre).

[0061] [Figure 11] Figure 11 shows the performance evaluation results of RedPA-Cre designed using 5 different red light switch proteins. (a~e) The response upon red irradiation is shown on the right side of the bar graph. The response in the dark is shown on the left side of the bar graph. The Fluxed-STOP fluc reporter gene was used in the experiment. The design of each composition (#1-4) is shown in (b) of Figure 5. The ratio (numerical value) of the response upon red light irradiation to the response in the dark is shown in the upper part of the figure. It should be noted that NS means P>0.05; * means P<0.05; ** means P<0.01; *** means P<0.001; **** means P<0.0001 (two-tailed unpaired t-test).

[0062] [ Fig.12 ] Fig.12 The results of evaluating the effect of adding biliverdin (BV) on the activity of RedPA-Cre are shown. The evaluation was performed using the bioluminescence intensity in HEK 293T cells into which RedPA-Cre and the Floxed-STOP fluc reporter gene were introduced as an index. In addition, NS indicates P>0.05 (two-way ANOVA based on multiple comparisons).

[0063] [ Fig.13 ] Fig.13The evaluation results of activating RedPA-Cre under various red light irradiation conditions are shown. HEK293T cells into which RedPA-Cre and Fluxed-STOP fluc reporter genes were introduced were irradiated with red light of various durations and intensities to evaluate the DNA recombination activity of RedPA-Cre. The area marked with an asterisk (*) corresponds to the time period for red light irradiation with a specified intensity, and the other parts correspond to the time period in the dark. The ratio of the response during each red light irradiation to the response in the dark is shown on the right side of the bar graph. In addition, **** indicates P < 0.0001 (one-way ANOVA based on multiple comparisons).

[0064] [ Fig.14 ] Fig.14 The results are shown in which three bicistronic systems (P2A, IRES_1, and IRES_2) used to express two different proteins on one vector were introduced into RedPA-Cre and compared using bioluminescence intensity as an indicator. The response when irradiated with red light is shown on the upper side of the bar graph, and the response in the dark is shown on the lower side of the bar graph. The floxed-STOP fluc reporter gene was used in the experiment. The ratio (numerical value) of the response when irradiated with red light to the response in the dark is shown on the right side of the bar graph.

[0065] [ Fig.15 ] Fig.15 The results of experiments using RedPA-Cre in mice (in vivo) are shown. (a) is an experiment for evaluating RedPA-Cre activation in mouse liver. RedPA-Cre and the Fluxed-STOP fluc reporter gene introduced into IRES_2 were introduced into ICR mice (50 mg in total) at a plasmid ratio of 1:4 and irradiated with 100Wm-2 red light for 16 hours, or raised in the dark. (b) Non-invasive red light irradiation was performed from outside the body of the mouse using a red LED light source. The mouse was irradiated with light in a transparent acrylic box (15cm×15cm) with a wire mesh on the bottom.

[0066] [ Fig.16 ] shows the amino acid sequence of sequence number 1. Shows the amino acid sequences of sequence numbers 61 and 62. Sequence numbers 1, 61 and 62 are respectively Figure 1 The amino acid sequences of the affibodies represented as Aff6, Aff6_V18F and Aff6_V18FΔN correspond to each other.

[0067] [ Fig.17 ] shows the amino acid sequence of sequence number 2. Sequence number 2 and Figure 1 The amino acid sequence of the photoreceptor protein denoted DrBphP corresponds to .

[0068] [ Fig.18 ] shows the DNA sequence (SEQ ID NO: 3) used in the synthesis of His6-Avi-DrBphP (PSM). In each sequence, the portion related to each domain is underlined.

[0069] [ Fig.19 ] shows the DNA sequence (SEQ ID NO: 4) used in the synthesis of His6-Avi-DrBphP.

[0070] [ Fig. 20 ] shows the DNA sequence (SEQ ID NO: 5) used in the synthesis of tetR-DrBphP (PSM).

[0071] [ Fig.21 ] shows the amino acid sequence of tetR-DrBphP (SEQ ID NO: 6).

[0072] [ Fig. 22 ] shows the DNA sequence (SEQ ID NO: 7) used in the synthesis of tetR-DrBphP.

[0073] [ Fig.23 ] shows the DNA sequence (SEQ ID NO: 8) used to synthesize 3xNLS-MS2-DrBphP-V5-His.

[0074] [ Fig.24 ] shows the DNA sequence (SEQ ID NO: 9) used to synthesize 3xNLS-DrBphP-MS2.

[0075] [ Fig.25 ] shows the DNA sequence (SEQ ID NO: 10) used to synthesize 3xNLS-p65-HSF1-DrBphP.

[0076] [ Fig.26 ] shows the amino acid sequence of 3xNLS-DrBphP-p65-HSF1 (SEQ ID NO: 59).

[0077] [ Fig. 27 ] shows the DNA sequence (SEQ ID NO: 11) used to synthesize 3xNLS-DrBphP-p65-HSF1.

[0078] [ Fig.28 ] shows the DNA sequence (SEQ ID NO: 12) used to synthesize NLS-CreN59-DrBphP.

[0079] [ Fig.29 ] shows the DNA sequence (SEQ ID NO: 13) used to synthesize NLS-DrBphP-CreC60.

[0080] [ Fig.30] shows the DNA sequence (SEQ ID NO: 14) used to synthesize NLS-DrBphP-CreN59.

[0081] [ Fig.31 ] shows the DNA sequence (SEQ ID NO: 15) used to synthesize NLS-CreN104-DrBphP.

[0082] [ Fig.32 ] shows the amino acid sequence of NLS-DrBphP-CreC106 (SEQ ID NO: 16).

[0083] [ Fig.33 ] shows the DNA sequence (SEQ ID NO: 17) used to synthesize NLS-DrBphP-CreC106.

[0084] [ Fig.34 ] shows the DNA sequence (SEQ ID NO: 18) used to synthesize NLS-DrBphP-CreN104.

[0085] [ Fig.35 ] shows the DNA sequence (SEQ ID NO: 19) used to synthesize Aff6-VP16-NLS.

[0086] [ Fig.36 ] shows the DNA sequence (SEQ ID NO: 20) used to synthesize Aff6_V18F-VP16-NLS.

[0087] [ Fig.37 ] shows the amino acid sequence of Aff6_V18FΔN VP16-NLS (SEQ ID NO: 21).

[0088] [ Fig.38 ] shows the DNA sequence (SEQ ID NO: 22) used for synthesizing Aff6_V18FΔN VP16-NLS.

[0089] [ Fig.39 ] shows the DNA sequence (SEQ ID NO: 23) used to synthesize Aff6_V18FΔN-3xFLAG-Cfluc.

[0090] [ Fig.40 ] shows the DNA sequence (SEQ ID NO: 24) used to synthesize 3xNLS-MS2-Aff6_V18FΔN-V5-His.

[0091] [ Fig.41 ] shows the DNA sequence (SEQ ID NO: 25) used to synthesize Aff6_V18FΔN-MS2-3xNLS.

[0092] [ Fig.42] shows the DNA sequence (SEQ ID NO: 26) used to synthesize 3xNLS-p65-HSF1-Aff6_V18FΔN.

[0093] [ Fig.43 ] shows the DNA sequence (SEQ ID NO: 27) used to synthesize Aff6_V18FΔN-p65-HSF1-3xNLS.

[0094] [ Fig.44 ] shows the DNA sequence (SEQ ID NO: 28) used to synthesize 3xNLS-MS2-2xAff6_V18FΔN.

[0095] [ Fig.45 ] shows the amino acid sequence of 2xAff6_V18FΔN-MS2-3xNLS (SEQ ID NO: 60).

[0096] [ Fig.46 ] shows the DNA sequence (SEQ ID NO: 29) used to synthesize 2xAff6_V18FΔN-MS2-3xNLS.

[0097] [ Fig.47 ] shows the DNA sequence (SEQ ID NO: 30) used to synthesize NLS-CreN59-Aff6_V18FΔN.

[0098] [ Fig.48 ] shows the DNA sequence (SEQ ID NO: 31) used to synthesize NLS-Aff6_V18FΔN-CreC60.

[0099] [ Fig.49 ] shows the DNA sequence (SEQ ID NO: 32) used to synthesize NLS-Aff6_V18FΔN-CreN59.

[0100] [ Fig.50 ] shows the amino acid sequence of NLS-CreN104-Aff6_V18FΔN (SEQ ID NO: 33).

[0101] [ Fig.51 ] shows the DNA sequence (SEQ ID NO: 34) used to synthesize NLS-CreN104-Aff6_V18FΔN.

[0102] [ Fig.52 ] shows the DNA sequence (SEQ ID NO: 35) used to synthesize NLS-Aff6_V18FΔN-CreC106.

[0103] [ Fig.53 ] shows the DNA sequence (SEQ ID NO: 36) used to synthesize NLS-Aff6_V18FΔN-CreN104.

[0104] [ Fig.54 ] shows the DNA sequence (SEQ ID NO: 37) used to synthesize NLS-CreN104-Aff6_V18FΔN-Venus.

[0105] FIG. 55 shows the DNA sequence (SEQ ID NO: 38) used for the synthesis of NLS-CreN104-Aff6_V18FΔN-P2A-NLS-DrBphP-CreC106.

[0106] FIG. 56 shows the DNA sequence (SEQ ID NO: 39) used for the synthesis of NLS-CreN104-Aff6_V18FΔN-IRES-NLS-DrBphP-CreC106.

[0107] FIG. 57 shows the DNA sequence (SEQ ID NO: 40) used for the synthesis of NLS-DrBphP-CreC106-IRES-NLS-CreN104-Aff6_V18FΔN. DETAILED DESCRIPTION

[0108] Hereinafter, the mode for implementing the present invention will be described in detail. It should be noted that the present invention is not limited to the following embodiment.

[0109] The set of the affibody and the photoreceptor protein of the present invention is a set that forms a complex with the photoreceptor protein in a light-dependent manner, and the wavelength of the light is 600 to 750 nm.

[0110] The photoreceptor protein used in the present invention is a photoreceptor protein possessed by prokaryotes and is known as a bacterial phytochrome. In the present invention, the photoreceptor protein is a protein sometimes abbreviated as BphP.

[0111] It is known that the structure of photoreceptor proteins changes in different long-wavelength ranges of light.

[0112] The photoreceptor protein is not particularly limited as long as it binds to the affibody under red light and dissociates from the affibody under near-infrared light.

[0113] The photoreceptor protein is not particularly limited, and an example thereof includes DrBphP, which is known as a red sensor protein derived from bacteria (Deinococcus radiodurans).

[0114] DrBphP has a light-receiving region (photosensory module: PSM) on the N-terminal side, and the state of DrBphP changes from Pr (dark state) to Pfr (light state) by irradiation with red light. In the light state, DrBphP binds to the affinity body.

[0115] In addition, taking DrBphP as an example, when DrBphP binds to an endogenous pigment as a cofactor and forms a complex with an affibody, the concentration required for the cofactor is sufficient at the concentration present in the cell, so there is no need to add an additional cofactor. Furthermore, when a complex is formed using the combination of the affibody of the present invention and a photoreceptor protein, there is an advantage that the complex is not formed in the dark, but specifically binds under red light. As disclosed in the examples, the combination of the affibody of the present invention and the photoreceptor protein can control the association of the split protein by turning on / off red light.

[0116] As for the photoreceptor protein, DrBphP preferably has:

[0117] (1) the amino acid sequence represented by SEQ ID NO: 2; or

[0118] (2) An amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 2.

[0119] In the present specification, "having 80% or more homology with the amino acid sequence represented by a sequence number" means that mutations are allowed in a specific sequence number.

[0120] Here, "80% or more homology" means that the amino acids repeated in the amino acid sequence represented by the specific sequence number are repeated at least 80% based on the total number of amino acids in the amino acid sequence represented by the sequence number.

[0121] For example, when the amino acid sequence represented by the sequence number contains 100 amino acids, a homology of 80% or more may refer to a sequence containing 80 amino acids, wherein 80 amino acids are identical (homology is 80%), or a sequence containing 120 amino acids, wherein 100 amino acids are identical (homology is 100%). Alternatively, a sequence containing 100 amino acids, wherein 80 amino acids are identical (homology is 80%).

[0122] In the present specification, when "having 80% or more homology with the amino acid sequence represented by a sequence number", the homology is preferably 85% or more, 90% or more, 95% or more, 98% or more, or 100%.

[0123] The case of "having 80% or more homology with the amino acid sequence represented by the sequence number" includes the case of having 100% homology, so unless otherwise specified, it may also be "the amino acid sequence represented by the sequence number 2".

[0124] When "having 80% or more homology with the amino acid sequence represented by a sequence number", one to a plurality of amino acids may be added, substituted or deleted in the amino acid sequence represented by the sequence number.

[0125] Here, in the case of a plurality of amino acids, the number may be less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, or less than 2. That is, in the amino acid sequence represented by the sequence number, 1, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, or 1 to 10 amino acids may be added, substituted, or deleted.

[0126] The upper limit of the number of amino acids that can be added, substituted or deleted in the amino acid sequence represented by the sequence number can be determined within the range of the homology as long as the homology is 80% or more, 85% or more, 90% or more, 95% or more, or 98% or more.

[0127] In addition, in this specification, the situation that an addition, substitution or deletion is included in a certain amino acid sequence refers to the addition (insertion), substitution or deletion at the end or non-end of the sequence. As far as the number of amino acids added, substituted or deleted is concerned, as long as the polypeptide obtained as a result exerts the effect of the present invention, it is not particularly limited. In addition, the site of addition, substitution or deletion can be 1 place, or it can be 2 or more places.

[0128] In the present specification, the homology with the amino acid sequence represented by the sequence number can be calculated by aligning the amino acids in the most consistent manner using methods known to those skilled in the art, and finding the ratio of amino acids repeated with the amino acid sequence represented by the sequence number.

[0129] In the present specification, homology can also be replaced by identity.

[0130] When the photoreceptor protein is DrBphP, the cysteine ​​at position 24 from the N-terminus in SEQ ID NO: 1 is a covalent binding site for biliverdin as a cofactor, and therefore it is preferably not mutated in order to bind to biliverdin.

[0131] In addition, it is known that DrBphP mainly includes 4 domains (PAS domain, GAF domain, PHY domain and HK domain). PAS domain, GAF domain and PHY domain are highly common in proteins collectively referred to as "bacterial phytochrome". On the other hand, it is known that the HK domain, which is also called the effector domain, is mostly different according to the bacterial phytochrome. Based on this information, mutations can also be set in each domain.

[0132] Affibody used in the present invention refers to a class of proteins consisting of about 58 amino acids, which are designed based on the Z domain of Staphylococcus aureus protein A. Affibody has a variable region, which can be said to be a binding site for photoreceptor protein, and a constant region for maintaining the structure of the affibody.

[0133] Affibodies used in the present invention may be (1) a peptide having the amino acid sequence represented by SEQ ID NO: 1, as a representative example.

[0134] In SEQ ID NO: 1, the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 are present on the surface of the Affibody in the helical bundle of the Affibody and participate in the binding to the photoreceptor protein. That is, in SEQ ID NO: 1, the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 constitute the variable region of the Affibody.

[0135] The amino acids in the affibody involved in binding to the photoreceptor protein are amino acids considered to be involved in binding to the photoreceptor protein that is in a state capable of binding to the affibody upon light excitation, and are amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 in the amino acid sequence represented by SEQ ID NO: 1.

[0136] These amino acids are preferably conserved in SEQ ID NO: 1, but even an Affimer in which a part of the amino acids are substituted with other amino acids has the ability to form a complex with the photoreceptor protein.

[0137] That is, the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35 in the amino acid sequence represented by SEQ ID NO: 1 may be mutated to other amino acids as long as the protein has the ability to form a complex with the photoreceptor protein.

[0138] The amino acids other than the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 in the amino acid sequence represented by SEQ ID NO: 1, that is, the amino acids at positions 1 to 8, 12, 15, 16, 19 to 23, 26, 29 to 31, 33, 34, and 36 to 58 can be said to be the amino acids in the constant region of the affinity body.

[0139] The amino acids other than the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 are amino acids that can be considered as constant region amino acids and are amino acids for maintaining the structure of the Affibody. Therefore, as long as the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 are a combination of amino acids that have the ability to bind to a photoreceptor protein, the amino acids at positions other than positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 in SEQ ID NO: 1 may be substituted or deleted, or other amino acids may be added as long as the structure of the Affibody is maintained.

[0140] Examples of deletions in an Affibody include deletions of amino acids at the N-terminus or C-terminus of the Affibody.

[0141] The amino acid deletion at the N-terminus or C-terminus may be a continuous or non-continuous deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids.

[0142] For example, 1 to 5 amino acids at the N-terminus or C-terminus may be deleted, 1 to 4 amino acids may be deleted, 1 to 3 amino acids may be deleted, 1 to 2 amino acids may be deleted, or 1 amino acid may be deleted. Among these amino acid deletions, consecutive amino acids may be deleted starting from the terminal amino acid.

[0143] One, two, three, four, five, six, seven, eight, nine, or ten amino acids at positions other than positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32, and 35 in SEQ ID NO: 1 may be substituted.

[0144] In addition, for the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35 in SEQ ID NO: 1, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids may be added as long as they have the ability to bind to the photoreceptor protein.

[0145] In the amino acid sequence represented by SEQ ID NO: 1 in the affinity body, the number of substituted, added or deleted amino acids can be 1 to 10, 1 to 9, 1 to 8, 1 to 7, or 1 to 6, and the upper limit can be 5 or less, 4 or less, 3 or less, 2 or less, or 1.

[0146] Among them, as long as the amino acids at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35 can obtain a structure having the ability to bind to its photoreceptor protein, any of the amino acids at positions 12, 15, 16, 19 to 23, 26, 29 to 31, 33 and 34 among the amino acids at positions 9 to 35 may be deleted.

[0147] The Affibody used in the present invention may be:

[0148] (2) an amino acid sequence represented by SEQ ID NO:1, wherein the amino acids corresponding to SEQ ID NO:1 are mutated at 1 to 5 positions among positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35;

[0149] (3) an amino acid sequence having 80% or more identity with the amino acid sequence of the amino acid sequence represented by SEQ ID NO:1 except for the amino acid sequences at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35;

[0150] (4) An amino acid sequence represented by SEQ ID NO: 1, wherein the corresponding amino acids in SEQ ID NO: 1 are mutated at 1 to 5 positions among positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35, and an amino acid sequence having 80% or more identity with the amino acid sequence of a portion other than positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35.

[0151] (5) an amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid corresponding to SEQ ID NO: 1 is mutated at position 18 and / or position 24;

[0152] (6) An amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid corresponding to SEQ ID NO: 1 is mutated at position 18 and / or position 24, and the amino acid sequence has an identity of 80% or more with the amino acid sequence other than positions 18 and 24.

[0153] (7) an amino acid sequence having an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M) at position 18 in the amino acid sequence represented by SEQ ID NO:1;

[0154] (8) An amino acid sequence represented by sequence number 1, which has an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M) at position 18, and has an amino acid sequence with a homology of more than 80% with the amino acid sequence of the portion other than position 18.

[0155] In addition, the Affibody used in the present invention may be:

[0156] (9) an amino acid sequence having an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M) at position 18 in the amino acid sequence represented by SEQ ID NO: 1, and wherein 1 to 5 amino acids at the N-terminus or C-terminus of SEQ ID NO: 1 are deleted,

[0157] The amino acid sequence may include one to five amino acids deleted from the N-terminus and the C-terminus of SEQ ID NO: 1.

[0158] According to the combination of the photoreceptor protein and the affinity body of the present invention, complex formation and dissociation can be precisely controlled by a simple step of irradiating and shielding light.

[0159] The wavelength of light used when the affibody and the photoreceptor protein form a complex in a light-dependent manner is within the range of 600 to 750 nm.

[0160] An appropriate wavelength is set depending on the existence state of the photoreceptor protein in a state where it receives light and binds to the affinity body, and in a state where it receives light but does not bind to the affinity body. In order to achieve a state where the photoreceptor protein binds to the affinity body, that is, a light state, within the above-mentioned wavelength range, the lower limit may be 620 nm or more, 630 nm or more, 640 nm or more, 650 nm or more, 660 nm or more, 670 nm or more, 680 nm or more, 690 nm or more, and the upper limit may be 740 nm or less, 730 nm or less, 720 nm or less, 710 nm or less, or 705 nm or less.

[0161] The preferred wavelength is within the range of 640 to 720 nm.

[0162] In the set of the photoreceptor protein and the affibody in the present invention, the affibody and the photoreceptor protein form a complex in a light-dependent manner, and the formation of the complex can also be reversibly released in a light-dependent manner.

[0163] An appropriate wavelength is set depending on the state of the photoreceptor protein in which it receives light and binds to the affinity body, and in which it receives light but does not bind to the affinity body. In order to achieve a state in which the photoreceptor protein does not bind to the affinity body, that is, a dark state, for example, light with a wavelength of 750 nm or more, which is near-infrared light, may be irradiated, or the combination of the photoreceptor protein and the affinity body may be placed in a dark place.

[0164] In this wavelength range, the lower limit may be 760 nm or more, 770 nm or more, 780 nm or more, or 790 nm or more, and the upper limit may be 820 nm or less, or 810 nm or less.

[0165] The combination of the photoreceptor protein and the affinity in the present invention forms a complex or dissociates depending on a specific wavelength. In the combination of the photoreceptor protein and the affinity in the present invention, the affinity and the photoreceptor protein form a complex in a red light-dependent manner, and thus a technology that can be precisely controlled and manipulated with red light can be provided. The combination of the photoreceptor protein and the affinity of the present invention that can be applied to the photomanipulation of various proteins is called "MagRed".

[0166] MagRed is a technology that uses light to freely control proteins related to life phenomena and disease treatment.

[0167] In addition, MagRed can provide a technology for photocontrol in mammalian cells without adding cofactors by using red light for photocontrol.

[0168] Hereinafter, in this specification, the combination of an affibody and a photoreceptor protein will be described as "MagRed".

[0169] MagRed has a photoreceptor protein and an affibody. By binding the photoreceptor protein and the affibody to a domain, the on / off function of the domain can be precisely controlled by irradiation or shielding of light.

[0170] The domains to which the photoreceptor protein and the affibody are bound are not particularly limited, as long as they are domains that are controlled by light and exert their functions.

[0171] Both or one of the photoreceptor protein and the affibody may be bound to a domain that is photocontrolled to exert its function.

[0172] When both the photoreceptor protein and the affibody are bound to a domain that exerts its function by light control, the photoreceptor protein and the affibody can be complexed by light control so that the domain that binds to the photoreceptor protein and the domain that binds to the affibody come into proximity and exert their function. The domain that binds to the photoreceptor protein and the domain that binds to the affibody may be domains that have different functions, or the domain that binds to the photoreceptor protein and the domain that binds to the affibody may be adjacent to each other and exert one function.

[0173] When the domain that binds to the photoreceptor protein and the domain that binds to the affibody have different functions, the two domains can function by being adjacent to each other, for example, a heterodimer can be mentioned. In addition, the domain that binds to the photoreceptor protein and the domain that binds to the affibody can also form a homodimer.

[0174] Alternatively, a portion of the domain that functions to form a multimer may be used as the domain that binds to the photoreceptor protein, and the remaining portion of the domain may be used as the domain that binds to the affibody.

[0175] In the case where a domain that binds to a photoreceptor protein and a domain that binds to an affibody play a role by being adjacent to each other, for example, one domain is split into two parts. In this case, if a protein having a certain role is split into two parts, one of the two parts is used as a domain that binds to a photoreceptor protein, and the other of the two parts is used as a domain that binds to an affibody, when the domains that bind to the photoreceptor protein and the affibody are controlled by light to form a bound body, the domain that is split into two parts can play the same function as the original domain before the split.

[0176] When one of the photoreceptor protein and the affibody is bound to a domain that is photocontrolled to exert its function, the other photoreceptor protein or the affibody, which is not bound to a domain that is photocontrolled to exert its function, can be bound to a recognition domain that orients the bound body to a desired site.

[0177] By binding the recognition domain to one of the photoreceptor protein or the affibody, the photoreceptor protein or the affibody to which the recognition domain binds can be oriented to a desired site.

[0178] By photocontrolling the photoreceptor protein or the affibody that has been oriented to a desired site, the other of the photoreceptor protein or the affibody can be bound, and the domain bound to the other can exert its function.

[0179] The recognition domain that orients the binding body to a desired location is not particularly limited, but a domain that recognizes nucleic acid is preferably used.

[0180] When a domain that recognizes nucleic acid is used, MagRed is oriented to a predetermined position by the domain that recognizes nucleic acid, thereby causing the domain that exerts its function by light control to also be oriented to a predetermined position, thereby exerting its function.

[0181] A domain other than the domain that binds the photoreceptor protein and the affibody may be used to exert the function of the domain that binds the photoreceptor protein and the affibody.

[0182] For example, a domain that binds to both a photoreceptor protein and an affibody can be controlled by light so that they exist in close proximity and exert their function by adding another domain, and a domain that binds to one of a photoreceptor protein and an affibody can also exert its function by adding another domain that does not bind to the photoreceptor protein and the affibody.

[0183] The binding of the photoreceptor protein, the affibody and other domains is not particularly limited, and may be covalently bound, or may be bound via a linker.

[0184] In addition, a plurality of domains may be bound to the photoreceptor protein and the affibody, or a plurality of domains may be linked and bound to the photoreceptor protein and the affibody. When a plurality of domains are linked, the binding between the domains may be through a linker.

[0185] As the linker, a known linker can be used.

[0186] As a linker, for example, a linker having an amino acid sequence containing a large amount of glycine and serine in its sequence is preferably used. A linker with glycine as the main component can be used, preferably a linker containing serine and threonine as hydrophilic amino acids. The linker is not particularly limited and can be composed of 2 to 16 amino acids.

[0187] As other domains, for example, a nuclear localization signal sequence, a 2A peptide sequence, an IRES sequence, etc. may be bound.

[0188] The domain that exerts its function by light control is not particularly limited, and examples thereof include nucleases, recombinases, polymerases, deaminases, proteases, kinases, phosphatases, antibodies and antibody-like molecules, and neurotoxins.

[0189] In the present invention, the photoreceptor protein and the affinity body may be a combination in which the domain related to the transcriptional activity of the gene is bound to the affinity body, and the recognition domain of the nucleic acid is bound to the photoreceptor protein.

[0190] The present invention may be a method for inhibiting or activating the expression of a target gene, the method comprising the step of irradiating and incubating the target gene and a set of the photoreceptor protein and the affibody according to the present invention with light.

[0191] In addition, the present invention may be a method for inhibiting or activating the expression of a target gene, the method comprising the steps of irradiating and incubating the target gene, the set of the photoreceptor protein and the affinity body according to the present invention, and the CRISPR-associated protein with light.

[0192] By binding a domain that recognizes a nucleic acid near a target gene to one of the sets of the photoreceptor protein and the affinity body according to the present invention, the set of the photoreceptor protein and the affinity body according to the present invention forms a conjugate by light irradiation, whereby the domain associated with the transcriptional activity of the gene bound to the other set of the photoreceptor protein and the affinity body according to the present invention functions, thereby being able to inhibit or activate the expression of the target gene.

[0193] In addition, by binding a domain that recognizes a CRISPR-related protein, preferably a guide RNA containing an MS2 aptamer in the stem-loop 2 of tracrRNA to one of the sets of the photoreceptor protein and the affibody according to the present invention, to an MS2 aptamer that is a recognition domain of a nucleic acid, one of the sets of the photoreceptor protein and the affibody according to the present invention is present in the vicinity of a target gene recognized by the CRISPR-related protein. By irradiating light, the set of the photoreceptor protein and the affibody according to the present invention forms a conjugate, whereby the domain associated with the transcriptional activity of the gene bound to the other of the sets of the photoreceptor protein and the affibody according to the present invention functions, and the expression of the target gene can be inhibited or activated.

[0194] As CRISPR-related proteins, proteins known in the past for use in gene editing are used, and other components such as guide RNA may also be included together with CRISPR-related proteins. As CRISPR-related proteins, for example, proteins that lack nuclease activity and nickase activity are preferably used. By making the guide RNA a sequence complementary to the gene near the target gene, the combination of the photoreceptor protein and the affinity body of the present invention is present near the target gene, and the expression of the target gene can be inhibited or activated.

[0195] When the functional domain, which is a domain related to the transcriptional activity of a gene, is a transcriptional activation domain or a transcriptional repression domain, the expression of the target gene is activated or inhibited.

[0196] In this specification, "gene expression" is used as a concept including both transcription to synthesize RNA using DNA as a template and translation to synthesize a polypeptide based on the RNA sequence.

[0197] As functional domains, VP64, MS2, p65 and HSF1 can be used. As functional domains equivalent to them, known transcription activation domains and adaptor binding proteins can also be used, for example, transcription activation domains and adaptor binding proteins disclosed in Nature (2015) 517, 583-588 and Nature protocols (2012) 7 (10), 1797-1807.

[0198] In the present invention, the following group may be used: a protein having a predetermined function is cleaved into two fragments and one of the fragments is bound to an affinity body,

[0199] The protein with the required function is split into two pieces, and the other piece binds to the light receptor protein.

[0200] The protein to be split into two pieces is not particularly limited as long as it is a protein that functions when the photoreceptor protein binds to the affibody.

[0201] As a non-limiting example, an example of a protein that can be split into two parts is the Cre protein.

[0202] As the Cre protein split into two segments, a conventionally known protein can be used, and for example, the protein described in International Publication No. 2016 / 167300 can be mentioned.

[0203] The Cre protein split into two segments is not particularly limited as long as the two segments can function through the binding of the photoreceptor protein and the affibody, and may be composed of the N-terminal fragment and the C-terminal fragment of the Cre protein.

[0204] The cleavage site of the Cre protein can appropriately adopt a conventionally known cleavage site.

[0205] In the present invention, the N-terminal fragment and the C-terminal fragment of the Cre protein bind to the photoreceptor protein and the affibody, respectively.

[0206] In the set of the photoreceptor protein and the affinity body of the present invention, the photoreceptor protein and the affinity body form a binding body by light irradiation, whereby the N-terminal side fragment of the Cre protein and the C-terminal side fragment of the Cre protein bound to them are reconstructed into the Cre protein, and the recombinase activity of the Cre protein is restored. Thus, the N-terminal side fragment of the Cre protein and the C-terminal side fragment of the Cre protein are used as a set of MagRed obtained by binding the Cre protein, which can be used for light-dependent gene recombination.

[0207] When the N-terminal fragment of the Cre protein and the C-terminal fragment of the Cre protein are used for gene recombination using the Cre protein, a gene recombination technique based on the Cre / loxP system is preferred.

[0208] That is, MagRed bound to the N-terminal fragment of the Cre protein and the C-terminal fragment of the Cre protein can be used in combination with a loxP sequence or a loxP mutant sequence to perform gene recombination in a light-dependent manner. As the loxP mutant, a nucleic acid having a sequence selected from any one of lox2722, lox66, lox71, JT15, and JTZ17 can be used.

[0209] The present invention also provides an animal having MagRed.

[0210] When developing medical technologies based on light manipulation, the bio-tissue penetration of light becomes important. MagRed has a great advantage because it can be controlled using red light (~660nm) and near-infrared light (~800nm) that have high bio-tissue penetration.

[0211] An animal having the MagRed may have a domain that binds to MagRed, or may have, in addition to the domain that binds to MagRed, another domain that functions together with the domain.

[0212] In addition, in the animal, MagRed may be present as a combination of MagReds, may be present as a nucleic acid encoding at least MagRed, or may be present as at least one expression vector into which MagRed is introduced.

[0213] Animals with MagRed can be photocontrolled by red light, and therefore have gene recombination activity in vivo. Even when animals with MagRed that can be photocontrolled by red light are irradiated with light from outside the body, gene recombination can be efficiently controlled.

[0214] That is, by turning light irradiation on and off, gene recombination can be precisely controlled by MagRed not only in vitro but also in vivo.

[0215] The animal into which MagRed is introduced is not particularly limited as long as it is a mammal, but rodents as experimental animals are preferred.

[0216] In the present invention, by incorporating MagRed, there is no particular limitation on the animals into which the MagRed is incorporated. For example, the activity of a gene can be knocked out by light stimulation, or conversely, a mutant gene can be restored to normal by light stimulation and its impact can be evaluated, or the activity of a reporter gene such as a fluorescent protein can be activated by light stimulation to mark biological tissues and the cells that constitute them.

[0217] When expressing MagRed in animals or cells, nucleic acids corresponding to the photoreceptor protein and the affibody are selected, respectively, and nucleic acids corresponding to the domains that bind to the photoreceptor protein and the affibody are selected, and the respective nucleic acids are linked in such a way that the photoreceptor protein and the desired domain, and the affibody and the desired domain can be expressed. For example, the respective nucleic acids can be introduced into expression vectors such as plasmids.

[0218] The present invention also provides a set of nucleic acids designed so that a photoreceptor protein and a desired domain, an affibody and a desired domain can each be expressed.

[0219] The nucleic acid designed so that the light receptor protein and the desired domain can be expressed, and the nucleic acid designed so that the affibody and the desired domain can be expressed can be present on one expression vector. In addition, the nucleic acids can be present on the expression vector in a manner such that each nucleic acid is connected, or in a manner such that the expression is controlled separately. In addition, the nucleic acid designed so that the light receptor protein and the desired domain can be expressed, and the nucleic acid designed so that the affibody and the desired domain can be expressed can also be present on different expression vectors. It can also be a nucleic acid designed so that the light receptor protein or the affibody and the desired domain are mediated by a linker.

[0220] In the present invention, the nucleic acid can be inserted downstream of the promoter of the expression vector directly, or after being digested with a restriction endonuclease, or after adding a linker.

[0221] The expression vector is not particularly limited, and examples thereof include plasmids derived from Escherichia coli (pBR322, pBR325, pUC12, pUC13, pUC18, pUC19, pUC118, pBluescript II, etc.), plasmids derived from Bacillus subtilis (pUB110, pTP5, pC1912, pTP4, pE194, pC194, etc.), plasmids derived from yeast (pSH19, pSH15, YEp, YRp, YIp, YAC, etc.), bacteriophages (λ phage, M13 phage, etc.), viruses (retrovirus, vaccinia virus, adenovirus, adeno-associated virus (AAV), cauliflower mosaic virus, tobacco mosaic virus, baculovirus, etc.), and cosmids.

[0222] The promoter can be appropriately selected according to the type of the host. When the host is an animal cell, for example, a promoter derived from SV40 (Simian Virus 40) or a promoter derived from CMV (Cytomegalovirus) can be used. When the host is Escherichia coli, for example, a trp promoter, a T7 promoter, a lac promoter, etc. can be used.

[0223] The expression vector may also include nucleic acids encoding DNA replication origin (ori), selection markers (antibiotic resistance, nutritional deficiency, etc.), enhancers, splicing signals, PolyA tailing signals, tags (FLAG, HA, GST, GFP, etc.), and the like.

[0224] In the present invention, a transformant can be obtained by transforming an appropriate host cell with an expression vector.

[0225] The host can be appropriately selected according to the relationship with the vector, for example, Escherichia coli, Bacillus subtilis, Bacillus bacteria, yeast, insects or insect cells, animal cells, etc. can be used. As animal cells, for example, HEK293T cells, CHO cells, COS cells, myeloma cells, HeLa cells, Vero cells can be used. With regard to transformation, it can be carried out according to known methods such as liposome transfection, calcium phosphate method, electroporation, microinjection, particle gun method, etc. according to the type of host.

[0226] The target polypeptide can be expressed by culturing the transformant according to a conventional method.

[0227] The protein from the transformant culture is purified by collecting the cultured cells, suspending them in an appropriate buffer, disrupting the cells by ultrasonic treatment, freeze-thaw, etc., and obtaining a crude extract by centrifugation and filtration. In the case where the polypeptide is secreted into the culture medium, the supernatant is collected.

[0228] Purification from a crude extract or culture supernatant can also be performed by a known method or a method based thereon (e.g., salting out, dialysis, ultrafiltration, gel filtration, SDS-PAGE, ion exchange chromatography, affinity chromatography, reverse-phase high performance liquid chromatography, etc.).

[0229] Example

[0230] Production of expression vector

[0231] All constructs expressing RedPA-Cre and Red-CPTS were cloned into pcDNA3.1 or pcDNA3.1 / V5-His vectors. All constructs related to the TetR-tetO system were cloned into pSV40 vectors. All constructs encoding sgRNA were cloned into pSPgRNA vectors with U6 promoter (Addgene plasmid #47108). The cDNA encoding codon-optimized Streptococcus pyogenes Cas9 was amplified from pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene plasmid #42230). In order to eliminate the nuclease activity of Cas9, D10A and H840A mutations were introduced into Cas9. The cDNA encoding MS2 (N55K) mutant and p65-HSF1 was amplified from MS2-P65-HSF1_GFP (Addgene plasmid #61423). The EGFP-Cre gene was amplified from pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40 (Addgene plasmid #105540). The cDNA encoding Cre recombinase was synthesized by Invitrogen. The cDNA encoding DrBphP, RpBphP1, and PpsR2 was synthesized by GenScript. The cDNA encoding Zdk1 and LDB-14 (nanoReD2) was synthesized by Eurofins Genomics. The cDNA encoding VP16-NLS and tetR was amplified from tetR-VP16-NLS / pSV40.

[0232] Preparation of ribosome display library of Affibody

[0233] The synthetic gene encoding the library of affibodies was constructed by ligating the sequence elements required for ribosome display after a 3-step PCR reaction. The dsDNA encoding the 1st and 2nd helices of the affibodies was assembled by annealing primers O1 and O2 with complementary 3' ends and enzymatically extending them. The randomized residues were encoded using the codons NNK (N = G, A, C, T; K = G, T). Then, overlap extension PCR was performed using primers O3 and O4, and the third helix was added using the initial reaction product as a template. In the third PCR, the resulting dsDNA encoding the library of affibodies was amplified using the T7 promoter by PCR using primers O5 and O6. At the same time, the base sequence containing the SecM extension pause sequence (AKFSTPVWISQAQGIRAGPQRLT) was amplified using pDgIIISecM-PURF1 as a template by PCR using primers O7 and O8. The two fragments were digested with TypeIIS restriction endonuclease BsmBI (NEB) and then connected. In order to avoid over-amplification and errors in PCR, KOD-Multi & Epi-DNA polymerase (Toyobo) was used, and the number of cycles in each PCR step was set to less than 5 cycles. Each reaction product and the connection product were separated by gel electrophoresis, purified with PureLink PCR purification kit (Invitrogen), and then the following reaction was performed.

[0234] Screening of Affibodies Based on Ribosome Display

[0235] The sequence encoding DrBphP-PSM was cloned into the pColdI vector (Takara Bio Inc.) containing an Avi tag following the His6 tag at the N-terminus. Escherichia coli C41 (DE3) strain (Lucigen, Wisconsin, USA) harboring pKT270 was transformed with pColdI-Avi-DrBphP-PSM. The transformed cells were cultured at 37°C with shaking at 200 rpm until OD590=0.45 in 30 ml of LB medium supplemented with ampicillin (100 mg / ml) and chloramphenicol (30 mg / ml), and cooled to room temperature. Then, isopropyl-β-D-thiogalactoside (IPTG, Wako Pure Chemical Industries, Ltd.) and biliverdin (BV, Frontier Scientific Inc.) were added to the culture solution at final concentrations of 0.5 mM and 100 μM, respectively. The cells were cultured in the dark at 16°C for 48 hours to express the protein. The cultured cells were recovered by centrifugation and dissolved in 2 ml of B-PER reagent (Thermo Fisher Scientific) containing 0.2 mg of lysozyme (Wako Pure Chemical Industries, Ltd.), 10 Units of DNase I (Thermo Fisher Scientific) and a protease inhibitor cocktail (Sigma-Aldrich) at room temperature for 10 minutes. The crude soluble extract was purified using a HisTrap FF column (GE Healthcare). Biotinylation of DrBphP-PSM was performed using BirA enzyme (BirA500, Avidity LLC) according to the manufacturer's protocol.

[0236] Affibody ribosome-protein fusion libraries were generated using the PURE system. A standard PURE translation mix was prepared as described above. In vitro transcription and translation reactions were performed at 37°C for 60 min, followed by 100 μL of TBS-MgCl. 2+ The reaction was stopped by adding 50 mM Tris-HCl, 50 mM MgCl2 and 150 mM NaCl, pH 7.5. On the other hand, 30 μL of streptavidin magnetic beads (Dynabeads M-280 Streptavidin, Invitrogen) were added with 200 μL of TBS-Mg 2+ The beads were washed once with 200 μL of TBS-MgSO. Biotinylated DrBphP-PSM protein was added to the washed beads, which were gently rotated and incubated at 4°C for 30 minutes. 2+The beads were washed once with buffer, and then the diluted reaction mixture obtained in the in vitro transcription and translation reaction was added. The resulting mixture was then exposed to light at 660 nm or 760 nm to convert the DrBphP-PSM into a light state (Pfr) or a dark state (Pr), respectively. After incubation at room temperature for 45 minutes with slow rotation, the beads were washed with 200 μL of TBS-Mg 2+ The beads were washed twice with buffer. In order to recover the concentrated ribosome and protein fusion, 200 μL of elution buffer (TBS buffer + 50 mM EDTA) was added to the beads, slowly rotated and incubated at room temperature for 30 minutes. The obtained eluate was subjected to standard phenol-chloroform extraction and isopropanol precipitation to remove the protein component. The purified RNA was reverse transcribed using primer O8 using SuperScript III (Thermo Fisher Scientific), and the concentrated cDNA library was regenerated using PCR using primers O5 and O8 using KOD-Multi&Epi-DNA polymerase. After repeated screening 6 times, the concentrated DNA library was sequenced using the Miseq Reagent Kit v.3 using an Illumina MiSeq instrument (150 cycles, 130 bp and 45 bp, double-end sequencing). The results are shown in Figure 6 .

[0237] The amino acid sequences (SEQ ID NOs: 41 to 50) of representative affibodies subjected to six rounds of screening are shown in Table 1. In addition, in Table 1, the amino acid sequence of No. 6 is identical to the amino acid sequence represented by SEQ ID NO: 1.

[0238] [Table 1]

[0239]

[0240] Next-generation sequencer-based analysis

[0241] Among the double-end sequencing reads, only the R1 reads become the object of subsequent analysis. The analysis of the sequence is performed using a custom python script. For further quality evaluation, the two correct sequences in the constant region of the affimer are retrieved. Evaluate whether the length between the two sites contains exactly 122 nucleotides. The sequence with the expected length is considered to be a complete affimer. Finally, the sequence of the affimer that is concentrated at a wavelength of 660nm and not detected at a wavelength of 760nm is selected.

[0242] Cell culture

[0243] HEK 293T cells and Neuro2a cells (ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma Aldrich) supplemented with 10% fetal bovine serum (FBS, HyClone), 100 units / mL penicillin, and 100 μg / mL streptomycin (Gibco) at 5% CO2 and 37°C. HeLa cells (ATCC) were cultured in minimal essential medium (Sigma Aldrich) supplemented with 10% FBS, 100 U / mL penicillin, and 100 μg / mL streptomycin at 5% CO2 and 37°C.

[0244] light source

[0245] Except for the split luciferase experiment, light irradiation was performed in a CO2 incubator. To irradiate the cells, a 660nm and 760nm LED array (CCS) was set at the bottom of the incubator, and 24-well and 96-well plates were placed on top of the LED array. A stabilized DC power supply (Kikusui Electronics Co., Ltd.) was used for current control of the LED. The time illumination pattern was made by an Arduino mega microcontroller board.

[0246] Gene expression system based on TetR-tetO system

[0247] For HeLa cells, 1.0 × 10 cells were cultured per well in the presence of 25 μM BV. 4 Cells were seeded in a 96-well multiwell plate (Greiner) and cultured at 37°C and 5% CO2 for 24 hours. Then, transfection was performed using Lipofectamine 3000 (Invitrogen). Plasmids encoding VP16-NLS, tetR and luciferase reporter system were transfected at a ratio of 1:1:1. The total amount of DNA was 0.1μg per well. As a control condition (Aff6-VP16-NLS(-)), Aff6 of Aff6-VP16-NLS was replaced with an irrelevant affinity (Zdk1). 24 hours after transfection, 100μL of culture medium was added to the sample and then irradiated with light at 37°C and 5% CO2. The red light sample was illuminated with 660nm pulsed light (1W / m 2) was incubated under the conditions of . In the dark, the multiwell plate in which HeLa cells were cultured was wrapped with aluminum foil and incubated at 5% CO2 and 37°C. After 24 hours of culture, the culture medium was replaced with 100 μL of HBSS (Gibco) containing 500 μM D-luciferin (Wako Pure Chemical Industries, Ltd.) as a substrate. After 30 minutes at room temperature, bioluminescence was measured using a luminescent microplate reader (Centro XS3 LB960, Berthold Technologies). When the SEAP reporter gene plasmid was used, the supernatant of the cells subjected to light irradiation was measured by the SEAP reporter gene assay (Roche Diagnostics). The results are shown in Figure 1 , Figure 7 and Figure 8 .

[0248] Split-luciferase assay with MagRed

[0249] In the presence of 25 μM biliverdin (BV), 4.0×10 5 HEK293T cells were seeded in 35mm / cell culture dishes (IWAKI) at a cell concentration of cells and cultured at 37°C and 5% CO2 for 24 hours. The plasmid encoding Nfluc-DrBphP and the plasmid encoding 3xFLAG-Aff6_V18FΔN-Cfluc were transfected at a ratio of 1:1. The total amount of DNA was 2.5μg per culture dish. When a plasmid encoding full-length firefly luciferase (fluc) was used as a control, the amount of DNA was 0.025μg per culture dish to make the dynamic range of bioluminescence intensity consistent. 24 hours after transfection, the culture medium was replaced with 2ml of HBSS supplemented with 200μM D-luciferin. After incubation at room temperature for 30 minutes, an LED array was used to irradiate 800nm ​​light (50W / m 2 ), DrBphP was photoconverted from the light state (Pfr) to the dark state (Pr). Then, a GloMax 20 / 20 illuminometer (Promega) was used to perform bioluminescence measurement at room temperature. In order to irradiate the cells with 660 nm light and stop the bioluminescence measurement, the sample culture dish was removed from the illuminometer. Then, a 660 nm LED array was used to irradiate the cells with 660 nm light (10 W / m 2 ), immediately put the sample culture dish back into the illuminometer and restart the bioluminescence measurement. The procedure of irradiating the cells with 800nm ​​light is the same as above. The results are shown in Figure 2 .

[0250] Luciferase reporter gene assay of CPTS

[0251] HEK 293T cells and Neuro-2a cells were cultured at 2.0 × 10 cells per well. 4 HeLa cells were plated at 1.0×10 4 The cells were inoculated into 96-well multiwell plates. The cells were cultured at 37°C and 5% CO2 for 24 hours. The plasmids encoding NLS-dCas9-NLS, MS2, p65-HSF1, sgRNA and luciferase reporter system were transfected at a ratio of 1:1:1:1:1. The total amount of DNA was 0.1 μg per well. The steps of MagRed light irradiation and bioluminescence detection were as described above. For the RpBphP1-PpsR2 / QPAS1 system, the red light sample was irradiated at 10 W / m 2 The cells were incubated under 760 nm pulse irradiation (1 minute light irradiation, 4 minutes light off). The other steps were as described above. Under the condition of adding biliverdin (BV) (BV(+)), the cells were inoculated in the presence of 25 μM BV and transfected as described above. 24 hours after transfection, 100 μL of culture medium supplemented with 25 μM BV was added to the sample. The remaining steps were as described above. The results are shown in Fig. 9 . The amino acid sequence and base sequence of NLS-dCas9-NLS are shown in sequence numbers 51 and 52. sgRNA is shown in sequence numbers 53 to 57. Sequence number 58 is the MS2 aptamer sequence of sgRNA. In addition, in sgRNA, the base sequence recorded on the 5' end side than GTTTTA is the target sequence.

[0252] The amino acid sequence of NLS-dCas9-NLS (SEQ ID NO: 51) is as follows: The underlined sequences represent the sequences of NLS and dCas9, respectively.

[0253] MYPYDVPDYAS PKKKRKV EAS DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNL IGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIV DEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEEN PINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDL DNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQE DFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLP NEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVE ISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRR YTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSP AIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQ NEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSCDKNRGKSDNVPSEEVVKKKMKNYW RQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLK SKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAXEQEIGKATAK YFFYSNIMNFFKTEITLANGEIRKRPLIETNGETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESIL PKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGIMERSSFEKNPIDFLEAKGY KEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHEKLKGSPEDNEQQLFVEQHK HYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTST KEVLDATLIHQSITGLYETRIDLSQLGGD S PKKKRKV EAS

[0254] The amino acid sequence of NLS-dCas9-NLS (SEQ ID NO: 52) is as follows. The underlined sequences represent the base sequences encoding NLS and dCas9, respectively.

[0255] ATGTACCCATACGATGTTCCAGATTACGCTTCG CCGAAGAAAAAGCGCAAGGTC GAAGCGTCC GAC AAGAAGTACAGCATCGGCCTGGCCATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGAGGAGTACAAGGTGC CCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTT CGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGAGGAAGAACCGG ATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGT CCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCA CGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATC TATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCG ACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGG CGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCC GGCGAGAAGAAGAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACT TCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCA GATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTG AGAGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACC TGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAG ATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACG GCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCT GAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGA AACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACA AGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCC CAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATG AGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGA CCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGA TCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAG GAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGC TGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAG GCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGAC GGCTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCC AGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCAT CCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAA ATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCA TCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCT GTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTG GACGCCATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACC GGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGC CAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCC GGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGA ACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGA TTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAAC GCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGT ACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAA CATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAAC GGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAG TGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGA TAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCT GTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCA TCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGA CCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGC GAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGA AGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGAT CATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTAC AACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAG CCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGC CACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGCGAC AGC CC CAAGAAGAAGAGAAAGGTG GAGGCCAGCTAA

[0256] The sequences of sgRNA (SEQ ID NOs: 53 to 57) are as follows: The underlined sequences represent the target sequence and the MS2 aptamer sequence, respectively.

[0257] P46 sgRNA_Gal4UAS (Sequence No. 53)

[0258] GAGTACTGTCCTCCGCGAATTC GTTTTAGAGCTA GGCCAACATGAGGATCACCCATGTCTGCAGGGC C TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT

[0259] P47 sgRNA_MYOD1 (Sequence No. 54)

[0260] GCCTGGGCTCCGGGGCGTTT GTTTTAGAGCTA GGCCAACATGAGGATCACCCATGTCTGCAGGGCC TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT

[0261] P48 sgRNA_HBG1 (Sequence No. 55)

[0262] GGCTAGGGATGAAGAATAAA GTTTTAGAGCTA GGCCAACATGAGGATCACCCATGTCTGCAGGGCC TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT

[0263] P49 sgRNA_IL1R2 (Sequence No. 56)

[0264] GTCCTTGGCCACTTCCCCATC GTTTTAGAGCTA GGCCAACATGAGGATCACCCATGTCTGCAGGGCC TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT

[0265] P50 sgRNA_ASCL1 (Sequence No. 57)

[0266] GCAGCCGCTCGCTGCAGCAG GTTTTAGAGCTA GGCCAACATGAGGATCACCCATGTCTGCAGGGCC TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT

[0267] Activation of endogenous genes based on Red-CPTS

[0268] For the transfection step, a mixture of sgRNAs targeting four endogenous genes was used, and the luciferase reporter gene was omitted, except as described above. 48 hours after transfection, total RNA extraction and reverse transcription PCR were performed using CellAmp DirectRNA Prep Kit (Takara Bio Inc.) and PrimeScript Real-Time Master Mix (Takara BioInc.). Quantitative PCR was performed using the StepOnePlus system (Thermo Fisher Scientific) and TaqMan Gene Expression Master Mix (Thermo Fisher Scientific). The expression level of the target gene was quantified using TaqMan primers and probes, and the GAPDH gene was measured as an endogenous control (Life Technologies. TaqMan Gene Expression Assay IDs are as follows. ASCL1: Hs04187546_g1, IL1R2: Hs01030384_m1, HBG1: Hs00361131_g1, MYOD1: Hs02330075_g1, GAPDH: Hs99999905_m1). In order to show the relative mRNA levels relative to the negative control transfected with an empty vector, the ΔΔCt method was applied.

[0269] RedPA-Cre luciferase reporter gene assay

[0270] HEK 293T cells were plated at 2.0 × 10 cells per well in the presence of 25 μM BV. 4 Cells were seeded into a 96-well multiwell plate and cultured at 37°C and 5% CO2 for 24 hours. Plasmids encoding a fusion protein containing CreN, a fusion protein containing CreC, and a luciferase reporter system were transfected at a ratio of 1:1:8. The total amount of DNA was 0.1 μg per well. Six hours after transfection, light irradiation was performed at 37°C and 5% CO2. In the MagRed system and nanoReD1 / 2 system, the red light sample was irradiated at 1 W / m 2 The cells were incubated under 660 nm pulse irradiation (1 min light on, 4 min light off). 2The red light sample was incubated under the conditions of 760nm pulse irradiation (1 minute light irradiation, 4 minutes light off). In the dark, the multiwell plate in which HEK 293T cells were cultured was wrapped with aluminum foil and incubated at 37°C and 5% CO2. After 18 hours of culture, the culture medium was replaced with 100μL HBSS (Gibco) containing 200μM D-luciferin (Wako Pure Chemical Industries, Ltd.) as a substrate. After 30 minutes at room temperature, bioluminescence was measured using a luminescent microplate reader (Centro XS3 LB 960, Berthold Technologies). The results are shown in Figures 5 and Figure 10 to Figure 14 .

[0271] RedPA-Cre fluorescent reporter gene experiment

[0272] HEK 293T cells were cultured at 0.8 × 10 5 Each well was inoculated into a 24-well plate and cultured at 37°C and 5% CO2 for 24 hours. The plasmids encoding NLS-CreN104-Aff6_V18FΔN-Venus, NLS-DrBphP(FL)-CreC106 and the fluorescent reporter system were transfected at a ratio of 1:1:8. The total amount of DNA was 0.5 μg per well. Six hours after transfection, the samples were irradiated with light at 37°C and 5% CO2. The red light sample was irradiated at 1 W / m 2Incubate under the conditions of 660nm pulse irradiation (1 minute light irradiation, 4 minutes off). In the dark, the multiwell plate in which HEK 293T cells were cultured was wrapped with aluminum foil and incubated at 5% CO2 and 37°C. After 24 hours of culture, the cells were fixed with PBS containing 4% paraformaldehyde for 15 minutes, and then incubated in a blocking solution (5% BSA, PBS containing 0.3% Triton-X100) at room temperature for 1 hour to block and improve the permeability of the cell membrane. Then, using mouse anti-mCherry antibody (mCherry Monoclonal Antibody conjugated with Alexa Fluor 594, Invitrogen, Cat#M11240, 1:1,000 dilution), the cells were immunostained in the blocking solution at room temperature for 1 hour while slowly shaking. After washing with PBS three times, staining with 300nM DAPI (Invitrogen) at room temperature for 15 minutes. Then, images were acquired using an inverted microscope (DMI6000B, Leica Microsystems) equipped with a 10x objective (Leica HCX PL FLUOTAR 10x / 0.30NAPH1) and an EM-CCD camera (Cascade II:512, Photometrics, Arizona, USA). Imaging of DAPI, GFP, and RFP channels was performed using A, L5, TX2 filter cubes (Leica Microsystems). The results are shown in Figure 3 and Figure 4 .

[0273] Fluorescence image processing

[0274] The fluorescent images obtained in the experiment were analyzed using imageJ and CellProfiler of FIJI version. The background of the image was removed using the Subtract background tool built into ImageJ. The nucleus was identified in the DAPI channel using a threshold of 5 to 20 pixel units of object diameter. In order to determine the populations of GFP-positive cells (GFP+) and mCherry-positive cells (mCh+), the average intensity of Venus and mCherry fluorescence in each cell nucleus was measured. The threshold of fluorescence intensity was determined in such a way that no mCh+ cells could be detected under control conditions. Then, the number of mCh+ cells was divided by the number of GFP+ cells and multiplied by 100 to calculate the ratio of mCh+ / GFP+ cells.

[0275] Evaluation of RedPA-Cre in mice

[0276] 10 μg of RedPA-Cre plasmid and 40 μg of bioluminescent reporter plasmid were mixed in TransIT-EE Hydrodynamic Delivery Solution (Mirus Bio LLC), and the plasmid was introduced into the liver of 4-week-old female ICR mice (Sankyo Labo Service) by hydrodynamic tail vein injection (HTVinjection). After 8 hours, the hair on the surface of the mouse abdomen was removed using a depilatory cream, and the mice were randomly divided into a dark group and a red light irradiation group. Then, the mice in the red light irradiation group were irradiated with an LED light source (660 nm; 100 W / m 2 ). Every 8 hours, the mice were temporarily returned to their home cages and fed for 1 hour. The mice in the dark group were placed in a light-proof home cage. Bioluminescence imaging was performed 25 hours after hydrodynamic tail vein injection. Before bioluminescence imaging, 200 mL of 100 mM D-luciferin was injected into the peritoneal cavity of the mice. Then, the mice were anesthetized with isoflurane (Wako Pure Chemical Industries, Ltd.). Five minutes after the injection of D-luciferin, bioluminescence images of the mice were obtained using a bioluminescence imager (Lumazone, Nippon Roper) equipped with an EMCD camera (Evolve 512, Photometrics). The results are shown in Figures 5 and Fig.15 .

Claims

1. A combination of an Affibody and a photoreceptor protein, wherein: The affibody forms a complex with the photoreceptor protein in a light-dependent manner, and the wavelength of the light is 600 to 750 nm.

2. The group according to claim 1, wherein The Affibody has an amino acid sequence of any one of the following (1) to (4): (1) the amino acid sequence represented by SEQ ID NO: 1; (2) an amino acid sequence represented by SEQ ID NO:1, wherein the amino acids corresponding to SEQ ID NO:1 are mutated at 1 to 5 positions among positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35; (3) an amino acid sequence having 80% or more identity with the amino acid sequence of the amino acid sequence represented by SEQ ID NO:1 except for the amino acid sequences at positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35; (4) An amino acid sequence represented by SEQ ID NO: 1, wherein the corresponding amino acids in SEQ ID NO: 1 are mutated at 1 to 5 positions among positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35, and an amino acid sequence having 80% or more identity with the amino acid sequence of a portion other than positions 9 to 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35.

3. The group according to claim 1, wherein: The Affibody has the following amino acid sequence (5) or (6): (5) an amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid corresponding to SEQ ID NO: 1 is mutated at position 18 and / or position 24; (6) An amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid corresponding to SEQ ID NO: 1 is mutated at position 18 and / or position 24, and the amino acid sequence has an identity of 80% or more with the amino acid sequence other than positions 18 and 24.

4. The group according to claim 1, wherein: The Affibody has the following amino acid sequence (7) or (8): (7) an amino acid sequence having an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M) at position 18 in the amino acid sequence represented by SEQ ID NO:1; (8) An amino acid sequence represented by sequence number 1, which has an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M) at position 18, and has an amino acid sequence with a homology of more than 80% with the amino acid sequence of the portion other than position 18.

5. The group according to claim 1, wherein: The Affibody has the following amino acid sequence (9): (9) An amino acid sequence represented by SEQ ID NO: 1, wherein at position 18, there is an amino acid selected from the group consisting of phenylalanine (F), tryptophan (W), histidine (H) and methionine (M), and 1 to 5 amino acids are missing from the N-terminus or C-terminus of SEQ ID NO:

1.

6. The set according to any one of claims 1 to 5, wherein: The light receptor protein is DrBphP.

7. The set according to any one of claims 1 to 5, wherein: Photoreceptor proteins have: (1) the amino acid sequence represented by SEQ ID NO: 2; or (2) An amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO:

2.

8. The set according to any one of claims 1 to 7, wherein: The domain associated with the transcriptional activity of the gene binds to one of the affibody and the photoreceptor protein, and the recognition domain of the nucleic acid binds to the other of the affibody and the photoreceptor protein.

9. The set according to any one of claims 1 to 7, wherein: One of the two fragments of the protein having a prescribed function is bound to the affinity body, and the other fragment of the two fragments of the protein having a prescribed function is bound to the photoreceptor protein.